December 13, 2016 / 5:39 PM / 7 months ago

BRIEF-Genticel reports final results of GTL001 phase 2 trial in HPV16/18-infected women

1 Min Read

Dec 13 (Reuters) - Genticel Sa :

* Genticel reports final results of GTL001 phase 2 trial in HPV16/18-infected women

* No statistical difference in viral clearance between treatment and placebo groups at any time point over 2 years in GTl001 phase 2 trial

* Other than first days following each vaccination, GTL001, imiquimod were generally well tolerated Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below